Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI.

doi:10.1016/j.jcf.2022.10.003

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Mar 2023

Schwarzenberg Sarah Jane, Vu Phuong T, Skalland Michelle, Hoffman Lucas R, Pope Christopher, Gelfond Daniel, Narkewicz Michael R, Nichols David P, Heltshe Sonya L, Donaldson Scott H, Frederick Carla A, Kelly Andrea, Pittman Jessica E, Ratjen Felix, Rosenfeld Margaret, Sagel Scott D, Solomon George M, Stalvey Michael S, Clancy John P, Rowe Steven M, Freedman Steven D

Abstract excerpt

BACKGROUND: Elexacaftor/tezacaftor/ivacaftor (ETI) improves pulmonary disease in people with cystic fibrosis (PwCF), but its effect on gastrointestinal symptoms, which also affect quality of life, is not clear. METHODS: PROMISE is a 56-center prospective, observational study of ETI in PwCF >12 years and at least one F508del allele. Gastrointestinal symptoms, evaluated by validated questionnaires: Patient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzodioxoles

Share to Constipation

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Mutation

Share to Pancreatic Elastase

Share to Quality of Life

Source

Open in PubMed Open full text

Identifiers

PMID: 36280527
DOI: 10.1016/j.jcf.2022.10.003
PMCID: PMC10144072

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI.PMID 36280527Read ↗

Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis.Semantic proximity Read ↗

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.Semantic proximity Read ↗

Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years – The RECOVER studySemantic proximity Read ↗

Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations.Semantic proximity Read ↗

A retrospective analysis of clinical parameters, safety and tolerability of Elexacaftor/Tezacaftor/Ivacaftor in a cohort of patients aged 6-17 years with cystic fibrosisSemantic proximity Read ↗

Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA.Semantic proximity Read ↗

Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor.Semantic proximity Read ↗

Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy.Semantic proximity Read ↗

Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.Semantic proximity Read ↗

Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational StudySemantic proximity Read ↗

Real-world effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis patients with Phe508del -gating and -residual function genotypes.Semantic proximity Read ↗

Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.